ArticleNature communications2019
Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells.Nature biomedical engineering · 2026Article
- Nanotechnology for the Treatment of Radiation Dermatitis: Advances and Translational Perspectives.International journal of nanomedicine · 2026Review
- Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy.Materials today. Bio · 2025Article
- Latest Nanoparticles to Modulate Hypoxic Microenvironment in Photodynamic Therapy of Cervical Cancer: A Review of In Vivo Studies.International journal of molecular sciences · 2025Review
- Phototherapy in cancer treatment: strategies and challenges.Signal transduction and targeted therapy · 2025Review
- Article
- In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing.Nature communications · 2024Article
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Combination of biodegradable hydrogel and antioxidant bioadhesive for treatment of breast cancer recurrence and radiation skin injury.Bioactive materials · 2024Article
- Oxygenated Wound Dressings for Hypoxia Mitigation and Enhanced Wound Healing.Molecular pharmaceutics · 2023Review
- Bone microenvironment regulative hydrogels with ROS scavenging and prolonged oxygen-generating for enhancing bone repair.Bioactive materials · 2023Article
- Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications.International journal of molecular sciences · 2023Review
- Characterization of Oxygen Nanobubbles and In Vitro Evaluation of Retinal Cells in Hypoxia.Translational vision science & technology · 2023Article
- Review
- Tumor-penetrating nanoplatform with ultrasound "unlocking" for cascade synergistic therapy and visual feedback under hypoxia.Journal of nanobiotechnology · 2023Article
- Nanotechnological strategies to increase the oxygen content of the tumor.Frontiers in pharmacology · 2023Review
- Editorial: Synthesis of novel photosensitizers for cancer theranostics.Frontiers in chemistry · 2023Article
- Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment.Frontiers in oncology · 2023Review
- Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy.Pharmaceutics · 2022Article
- Oxygen tank for synergistic hypoxia relief to enhance mitochondria-targeted photodynamic therapy.Biomaterials research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia-based agents (HBAs), such as anaerobic bacteria and bioreductive prodrugs, require both a permeable and hypoxic intratumoural environment to be fully effective. To solve this problem, herein, we report that perfluorocarbon nanoparticles (PNPs) can be used to create a long-lasting, penetrable and hypoxic tumour microenvironment for ensuring both the delivery and activation of subsequently administered HBAs. In addition to the increased permeability and enhanced hypoxia caused by the PNPs, the PNPs can be retained to further achieve the long-term inhibition of intratumoural O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.